Melanoma is a complex and highly malignant disease that can cause itching or bleeding, as well as ulcers and pain in some patients.
"Eat"
-
-
Apparatus
The "hand speed" is extremely fast, and scientists create a DNA robot arm that can move at a high speed
DNA nano robot system is one of the nano machines, and has been continuously developed in recent years. In recent years, in the journal Science, we saw another "feat" realized by DNA nano robot - researchers used electric field to accelerate the movement speed of DNA robot system.
-
Apparatus
Nature Medicine publishes results of H-drug combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma
H-Drugs in the leading international journal again!
-
Medical
New Treatment For Childhood Brain Tumours, Tovorafenib, Shows Promising Results With An Efficiency Rate Of 91%!
According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.
-
Blood cancer is a very complicated disease and should be treated in a timely manner to improve your disease and health condition and to gradually relieve your symptoms.
-
Once a stroke has occurred, if not detected and treated in time, it can have very serious and dire consequences for the patient. But for elderly people who have had a stroke, in addition to timely treatment, diet is also very important during recovery.
-
Apparatus
Stavudol Paediatric Indication Approved For The Treatment Of Children Aged 3 Months And Older With Complicated Intra-Abdominal Infections
There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.
-
According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!
-
Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.
-
Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.